Sugi Predict

Sugi Predict / Compounds / SCHEMBL22208176

SCHEMBL22208176

SCHEMBL22208176

Nc1c(C(=O)O)cnc(Cl)c1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HAVCR2 Q8TDQ0 1/20 0.47
▸ KDM4E B2RXH2 5/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ KEAP1 Q14145 2/20 0.42
▸ NFE2L2 Q16236 1/20 0.42
▸ GABRP O00591 4/20 0.41
▸ GABRD O14764 4/20 0.41
▸ GABRA1 P14867 4/20 0.41
▸ GABRB1 P18505 4/20 0.41
▸ GABRG2 P18507 4/20 0.41
▸ GABRB3 P28472 4/20 0.41
▸ GABRA5 P31644 4/20 0.41
▸ GABRA3 P34903 4/20 0.41
▸ GABRA2 P47869 4/20 0.41
▸ GABRB2 P47870 4/20 0.41
▸ GABRA4 P48169 4/20 0.41
▸ GABRE P78334 4/20 0.41
▸ GABRA6 Q16445 4/20 0.41
▸ GABRG1 Q8N1C3 4/20 0.41
▸ GABRG3 Q99928 4/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30064870 1.00 HAVCR2 (0.47) HAVCR2KDM4EKMT2AKEAP1NFE2L2
SCHEMBL25309720 0.85 ALDH1A1 (0.34) HAVCR2KDM4EKMT2AKEAP1NFE2L2
SCHEMBL19493916 0.85 NNMT (0.40) HAVCR2
SCHEMBL30064974 0.85 NNMT (0.40) HAVCR2
SCHEMBL18398775 0.82 KEAP1 (0.46) HAVCR2KDM4EKMT2AKEAP1NFE2L2
SCHEMBL27185426 0.81 KEAP1 (0.42) HAVCR2KDM4EKMT2AKEAP1NFE2L2
SCHEMBL29418647 0.81 KEAP1 (0.44) HAVCR2KDM4EKMT2AKEAP1NFE2L2
SCHEMBL391794 0.81 KEAP1 (0.44) HAVCR2KDM4EKMT2AKEAP1NFE2L2
SCHEMBL27716685 0.81 HAVCR2 (0.50) HAVCR2KDM4EKMT2AKEAP1NFE2L2
SCHEMBL30391898 0.80 TSHR (0.42) KDM4EALDH1A1MAPTCASP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630566-B2 KRas G12D inhibitors Mirati Therapeutics, Inc. (US) 2026-05-19 — — US disclosed
US-20260109716-A1 CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO ARVINAS OPERATIONS, INC. (US) 2026-04-23 — — US disclosed
EP-4655073-A2 CEREBLON-BASED KRAS DEGRADING PROTACS ANS USES RELATED THERETO Arvinas Operations, Inc. (US) 2025-12-03 — — EP disclosed
US-12448399-B2 Cereblon-based KRAS degrading PROTACs and uses related thereto ARVINAS OPERATIONS, INC. (US) 2025-10-21 — — US disclosed
US-20250206732-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS ARVINAS OPERATIONS, INC. 2025-06-26 — — US disclosed
WO-2025123007-A1 RAS INHIBITORS AND METHODS OF USE THEREOF KESTREL THERAPEUTICS INC. (US) 2025-06-12 — — WO disclosed
WO-2025024732-A1 COMPOUNDS USEFUL IN THE TREATMENT OF KRAS MEDIATED DISORDERS ARVINAS OPERATIONS, INC. (US) 2025-01-30 — — WO disclosed
US-20240409558-A1 IRREVERSIBLE INHIBITORS OF KRAS BIOMEA FUSION, INC. 2024-12-12 — — US disclosed
US-20240309020-A1 KRAS G12D INHIBITORS ARRAY BIOPHARMA INC. 2024-09-19 — — US disclosed
US-20240293558-A1 KRAS INHIBITOR CONJUGATES ERASCA, INC. 2024-09-05 — — US disclosed
US-20230077225-A1 KRAS G12D INHIBITORS Mirati Therapeutics, Inc. 2023-03-09 — — US disclosed
US-11548888-B2 KRas G12C inhibitors Mirati Therapeutics, Inc. (US) 2023-01-10 — — US disclosed
WO-2023274324-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR, INTERMEDIATE THEREOF, AND APPLICATION THEREOF 上海艾力斯医药科技股份有限公司 2023-01-05 — — WO disclosed
WO-2022266206-A1 KRAS INHIBITOR CONJUGATES ERASCA, INC. (US) 2022-12-22 — — WO disclosed
WO-2022266206-A1 KRAS INHIBITOR CONJUGATES ERASCA, INC. (US) 2022-12-22 — — WO disclosed
EP-4021444-A1 KRAS G12D INHIBITORS Mirati Therapeutics, Inc. (US) 2022-07-06 — — EP disclosed
EP-3908283-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2021-11-17 — — EP disclosed
WO-2021041671-A1 KRAS G12D INHIBITORS Mirati Therapeutics, Inc. (US) 2021-03-04 — — WO disclosed
US-20200331911-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. 2020-10-22 — — US disclosed
WO-2020146613-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2020-07-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12448399-B2 Cereblon-based KRAS degrading PROTACs and uses related thereto CRBN, KRAS, WEE1 HAVCR2 3622/4885KDM4E 1273/4885KMT2A 659/4885
US-20230077225-A1 KRAS G12D INHIBITORS KRAS, NRAS, HRAS HAVCR2 2111/4885KDM4E 3340/4885KMT2A 1755/4885
US-20240293558-A1 KRAS INHIBITOR CONJUGATES KRAS, MDM2, NRAS HAVCR2 1549/4885KDM4E 3526/4885KMT2A 1102/4885
US-12630566-B2 KRas G12D inhibitors KRAS, NRAS, HRAS HAVCR2 3592/4885KDM4E 2825/4885KMT2A 2950/4885
US-20240409558-A1 IRREVERSIBLE INHIBITORS OF KRAS KRAS, NRAS, TP53 HAVCR2 557/4885KDM4E 3532/4885KMT2A 1706/4885
US-11548888-B2 KRas G12C inhibitors KRAS, NRAS, HRAS HAVCR2 1990/4885KDM4E 3689/4885KMT2A 2081/4885
US-20200331911-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS HAVCR2 1990/4885KDM4E 3689/4885KMT2A 2081/4885
US-20250206732-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS KRAS, MDM2, VHL HAVCR2 1896/4885KDM4E 2092/4885KMT2A 1675/4885
US-20260109716-A1 CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO KRAS, CRBN, HRAS HAVCR2 2425/4885KDM4E 1792/4885KMT2A 1366/4885
US-20240309020-A1 KRAS G12D INHIBITORS KRAS, NRAS, HRAS HAVCR2 2111/4885KDM4E 3340/4885KMT2A 1755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.